Baker Bros. Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Baker Bros. Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,271,917	Closed	-$144M	–	124
2021 Q2	$144M	Buy	2,271,917 +597,913	+36%	+$30.9M	0.63%	16
2021 Q1	$71.8M	Buy	1,674,004 +777,453	+87%	+$36.8M	0.31%	31
2020 Q4	$51.3M	Hold	896,551	–	–	0.19%	34
2020 Q3	$27M	Hold	896,551	–	–	0.11%	44
2020 Q2	$29.3M	Hold	896,551	–	–	0.13%	41
2020 Q1	$24M	Buy	896,551 +399,582	+80%	+$14.2M	0.15%	38
2019 Q4	$15.2M	Buy	496,969 +183,244	+58%	+$5.07M	0.08%	49
2019 Q3	$7.56M	Hold	313,725	–	–	0.05%	55
2019 Q2	$7.95M	Hold	313,725	–	–	0.05%	57
2019 Q1	$6.12M	Buy	313,725 +117,647	+60%	+$1.85M	0.04%	56
2018 Q4	$2.59M	Hold	196,078	–	–	0.02%	68
2018 Q3	$3.49M	Hold	196,078	–	–	0.02%	79
2018 Q2	$4.31M	Buy	+196,078	New	+$4.5M	0.03%	83

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baker Bros. Advisors's APLS Position: Q3 2021 in Review

Baker Bros. Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 2,271,917 shares — an estimated $144M sold.

Baker Bros. Advisors first reported a position in APLS in Q2 2018 and held it in 13 quarters. The position peaked at $144M in Q2 2021. 180 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

Baker Bros. Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Baker Bros. Advisors sold 2,271,917 Apellis Pharmaceuticals shares in Q3 2021, an estimated $144M.
Baker Bros. Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 13 quarters.
Baker Bros. Advisors's Apellis Pharmaceuticals position peaked at $144M in Q2 2021.
180 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.